Sponsors
The bill strengthens and speeds FDA recall authority—including for biologics—to better protect patients, but expands regulatory reach and compliance costs and may increase the risk of supply disruptions for manufacturers, health systems, and patients.
Patients with chronic conditions and hospitals/health systems will have clearer FDA authority to order recalls or cease distribution for a broader set of drugs (beyond previously limited 'controlled substances'), improving the ability to remove unsafe or tainted medications quickly.
Patients (including those using biologics) and hospitals/health systems will benefit because adding the CBER Director to officials authorized to exercise emergency recall/distribution-stopping authority speeds decision-making for biologic products (e.g., vaccines, blood products).
Manufacturers and importers face broader recall and import restrictions across more products, which may increase costs and risk temporary drug supply interruptions for hospitals and patients.
Businesses previously regulated under narrower 'controlled substances' language (including some state-regulated entities and financial institutions) will face an increased compliance burden as the broader recall authority expands regulatory reach.
Based on analysis of 2 sections of legislative text.
Broadens certain FDA stop-distribution/recall and import/export authorities by replacing "controlled substances" with "drugs" and adds the CBER Director as an authorized official.
Introduced March 18, 2026 by Maxine Dexter · Last progress March 18, 2026
Amends existing FDA law to broaden certain enforcement and import/export authorities from “controlled substances” to all “drugs,” and adds the Director of the Center for Biologics Evaluation and Research (or a senior official) to the list of officials who may issue cease-distribution and recall orders. The changes adjust two statutory provisions to let the FDA apply the same stop-distribution/recall and import/export consequences to drugs generally (including biological products) as previously applied only to controlled substances. No new funding, deadlines, or reporting requirements are created.